# Chinese Medicinal Component Relieves CIPN and Mitochondria Function

> **NCT07693374** · NA · WITHDRAWN · sponsor: **Taiwan Municipal An-Nan Hospital-China Medical University**

## Conditions studied

- Breast Cancer
- Chemotherapy-induced Peripheral Neuropathy (CIPN)

## Interventions

- **DRUG:** Moutan cortex
- **DRUG:** sham moutan cortex

## Key facts

- **NCT ID:** NCT07693374
- **Lead sponsor:** Taiwan Municipal An-Nan Hospital-China Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-08-01
- **Primary completion:** 2025-08-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Initial prep showed that formulation, QC, and cost for high-dose paeonol/Cortex Moutan exceeded the budget. Also, recruiting patients with chemotherapy-induced peripheral neuropathy was limited. To ensure safety, enrollment did not officially launch.
- **Last updated:** 2026-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07693374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07693374, "Chinese Medicinal Component Relieves CIPN and Mitochondria Function". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07693374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*